Patents Assigned to INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD)
  • Patent number: 10849943
    Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: December 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS
    Inventors: Philippe Despres, Gilles Gadea, Patrick Mavingui, Wildriss Viranaicken
  • Publication number: 20200360334
    Abstract: The present invention relates to compound of formula (I): wherein R is O—R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, —CO—(C1-C21)alkyl or —CO—(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a —CO—(C11-C21)alkyl or —CO—(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.
    Type: Application
    Filed: November 12, 2018
    Publication date: November 19, 2020
    Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS), Ecole Nationale Superieure de Chimie, Institut de Recherche Pour le Developpement (IRD), Universite D'Aix-Marseille, Communaute Universites et Etablissements Universite Cote D Azur
    Inventors: Céline Crauste, Joseph Vercauteren, Fransisco Veas, Thierry Durand, Nicolas Blondeau
  • Patent number: 10590174
    Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: March 17, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Gilles Gadea, Michael Girardot, Philippe Despres
  • Patent number: 9873715
    Abstract: The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C1-C6) alkyl or —C(O)NH—(C1-C6) alkyl group. The invention also relates to the method for preparing said compound, to a pharmaceutical composition containing same, and to the use thereof as a drug, particularly for cancer treatment.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: January 23, 2018
    Assignees: PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Isabelle Carletti, Georges Massiot
  • Patent number: 9855321
    Abstract: The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the N-terminal portion of the VAR2CSA protein of different parasitic families or lines of Plasmodium falciparum, and to their use in the prevention of pregnancy-associated malaria. The invention also relates to immunogenic compositions and to vaccines useful for preventing malaria in pregnant women.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: January 2, 2018
    Assignee: INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD)
    Inventors: Nicaise Tuikue Ndam, Philippe Deloron, Justin Doritchamou
  • Patent number: 9765406
    Abstract: The oligonucleotide of sequence SEQ ID No.1: 5?-CTAGAGATCCCTCAGA-3?, and the complementary sequence thereof of sequence SEQ ID No.2: 5?-TCTGAGGGATCTCTAG-3? useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 19, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Martine Peeters, Lucie Etienne
  • Patent number: 9730442
    Abstract: The present invention relates to the use of 4-phenylbutyric acid, or one of the salts thereof, for improving the resistance of plants to harmful biological organisms, in particular to bacteria, viruses and nematodes, and for inhibiting hypersensitive cell death induced by such harmful biological organisms. The present invention also relates to the use of 4-phenylbutyric acid, or one of the salts thereof, as an antimicrobial agent for preventing or treating plant diseases caused by phytopathogens.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 15, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD)
    Inventors: Jean-Luc Cacas, Antony Champion
  • Patent number: 9540425
    Abstract: The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 10, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DéVELOPPEMENT (IRD)
    Inventors: Nicaise Tuikue Ndam, Philippe Deloron, Sedami Ursula Alix Carine Gnidéhou, Mickaël Quiviger, Pascal Bigey, Daniel Scherman
  • Patent number: 9493811
    Abstract: The present invention provides a method for determining the amino acid polymorphisms of heavy gamma chain of immunoglobulins G by a proteomic approach. This method distinguishes the immunoglobulins of the mother and those of the newborn in a blood sample obtained during the first months of the child's life. The invention also relates to the use of this method in the early diagnosis of vertically transmitted diseases in the neonate. The invention also provides peptides distinctive of G3m and IGHG3 alleles, and a kit comprising said peptides.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: November 15, 2016
    Assignees: INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD), UNIVERSITE PARIS DESCARTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Florence Migot-Nabias, Celia Dechavanne, Francois Guillonneau, Jean-Michel Dugoujon, Marie-Paule Lefranc
  • Publication number: 20160266023
    Abstract: A unit for measuring the falling speed of particles in suspension in a fluid comprises a sealed container having an open compartment containing fluid, and a sealed compartment, and, in the sealed compartment, at least three electromagnetic radiation emitters distributed along a longitudinal axis of the open compartment and oriented according to a radiation axis crossing the open compartment at different heights along the longitudinal axis, an equal number of receivers distributed along the longitudinal axis, each receiver placed in the radiation axis of a corresponding emitter, and a system for acquiring data connected to the receivers which is used to obtain the falling speed of the particles and the change of same as a function of the height in the open compartment and as a function of time, said change quantifying the flocculation of the particles.
    Type: Application
    Filed: October 16, 2014
    Publication date: September 15, 2016
    Applicant: Institut de Recherche Pour le Developpement (IRD)
    Inventors: Nicolas Gratiot, Bernard Mercier, Cedric Legout, Valentin Wendling, Catherine Coulaud, Henri Mora
  • Publication number: 20150376222
    Abstract: The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosaccharide or disaccharide residue are, independently, optionally substituted for a (C1-C6) alkyl or —C(O)NH—(C1-C6) alkyl group. The invention also relates to the method for preparing said compound, to a pharmaceutical composition containing same, and to the use thereof as a drug, particularly for cancer treatment.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 31, 2015
    Applicants: PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Isabelle CARLETTI, Georges MASSIOT
  • Patent number: 9222097
    Abstract: The invention relates to the use of genes which, in plants, encode proteins with a functional diversity in terms of silencing, comprising the selection of the gene with the level of effectiveness in order to construct a plant viral vector having the function of overexpressing or silencing particular genes.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: December 29, 2015
    Assignee: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Christophe Brugidou, Christelle Sire
  • Publication number: 20150320772
    Abstract: The present invention relates to acetylsalicylic acid or a salt thereof, at a concentration comprised between 200 and 4800 ?M, for use in the prevention and/or treatment of diabetic wounds.
    Type: Application
    Filed: December 18, 2013
    Publication date: November 12, 2015
    Applicants: LABORATOIRES URGO, INSERM, Institut de Recherche pour le Développement (IRD), Université Paul Sabatier Toulouse III
    Inventors: Agnes Coste, Christophe Dardenne, Bernard Pipy
  • Publication number: 20150201618
    Abstract: The present invention relates to the use of 4-phenylbutyric acid, or one of the salts thereof, for improving the resistance of plants to harmful biological organisms, in particular to bacteria, viruses and nematodes, and for inhibiting hypersensitive cell death induced by such harmful biological organisms. The present invention also relates to the use of 4-phenylbutyric acid, or one of the salts thereof, as an antimicrobial agent for preventing or treating plant diseases caused by phytopathogens.
    Type: Application
    Filed: July 10, 2013
    Publication date: July 23, 2015
    Applicant: INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD)
    Inventors: Jean-Luc Cacas, Antony Champion
  • Publication number: 20140178916
    Abstract: The present invention provides a method for determining the amino acid polymorphisms of heavy gamma chain of immunoglobulins G by a proteomic approach. This method distinguishes the immunoglobulins of the mother and those of the newborn in a blood sample obtained during the first months of the child's life. The invention also relates to the use of this method in the early diagnosis of vertically transmitted diseases in the neonate. The invention also provides peptides distinctive of G3m and IGHG3 alleles, and a kit comprising said peptides.
    Type: Application
    Filed: August 10, 2012
    Publication date: June 26, 2014
    Applicants: INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE PARIS DESCARTES
    Inventors: Florence Migot-Nabias, Celia Dechavanne, Francois Guillonneau, Jean-Michel Dugoujon, Marie-Paule Lefranc
  • Patent number: 8697637
    Abstract: The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: April 15, 2014
    Assignee: Institut de Recherche pour le Developpement (IRD)
    Inventors: Marthe Dorothée Misse Brumas, Natthanej Luplertlop, Hans Yssel, Frédéric Thomas, François Renaud
  • Patent number: 8574598
    Abstract: The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 et SEQ ID No. 11 and coding for a protein respectively exhibiting a sequence SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 et SEQ ID No. 12. The invention can be used for over-expression of the genes of Leishmania coding for an excretion/secretion antigen.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: November 5, 2013
    Assignee: Institut de Recherche Pour le Developpement (IRD)
    Inventors: Jean-Loup Lemesre, Mireille Cavaleyra, Denis Sereno, Philippe Holzmuller
  • Publication number: 20130129767
    Abstract: The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.
    Type: Application
    Filed: July 29, 2011
    Publication date: May 23, 2013
    Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Nicaise Tuikue Ndam, Philippe Deloron, Sedami Ursula Alix Carine Gnidéhou, Mickaël Quiviger, Pascal Bigey, Daniel Scherman
  • Publication number: 20130085268
    Abstract: The invention provides a composition for the inoculation in a plant of agrobacteria transfected by expression vectors, in order to produce in said plant a protein of interest or a derivative of said protein, by deletion or by mutation, characterised in that it comprises agrobacteria transfected by at least one expression vector, comprising a nucleotide sequence insert that codes for said protein or a derivative of said protein, and agrobacteria transfected by a plurality of expression vectors, each comprising at least one nucleotide sequence insert that codes for proteins having a silencing suppressor effect.
    Type: Application
    Filed: May 26, 2011
    Publication date: April 4, 2013
    Applicants: Institut de L'Environnement et de Recherches Agricoles, Institut de Recherche pour le Developpement (IRD)
    Inventors: Christophe Brugidou, Jean-Loup Lemesre, Denis Fargette, Drissa Sereme, Moumouni Konate, Gnissa Konate
  • Publication number: 20120295844
    Abstract: The present invention relates the use of aprotinin in the treatment of parasitic diseases or infections that affect domesticated mammals, in particular the cattle, especially bovines. In particular, aprotinin finds application in the fight against pathogenic effects induced by parasites in the Trypanosomatidae family, such as the protozoa that belong to the Trypanosoma genus or Leishmania genus. The invention also relates to the use of aprotinin for the prognosis of bovine tolerance to trypanosomosis infections.
    Type: Application
    Filed: January 21, 2011
    Publication date: November 22, 2012
    Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: David Berthier, Gerard Cuny, Sophie Thevenon, Isabelle Chantal, Anne Boissiere